

Hypoparathyroidism - Pipeline Review, H1 2020

<https://marketpublishers.com/r/HD54DD646F9EN.html>

Date: May 2020

Pages: 70

Price: US\$ 2,000.00 (Single User License)

ID: HD54DD646F9EN

Abstracts

Hypoparathyroidism - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism – Pipeline Review, H1 2020, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape.

Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction), and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes artificial form of the hormone that can be administered as replacement, calcium replacement or vitamin.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoparathyroidism – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hypoparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoparathyroidism (Hormonal Disorders) pipeline guide also reviews of key

players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 5 and 4 respectively.

Hypoparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoparathyroidism (Hormonal Disorders).

The pipeline guide reviews pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hypoparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hypoparathyroidism (Hormonal Disorders)

therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hypoparathyroidism (Hormonal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hypoparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Hypoparathyroidism - Overview
- Hypoparathyroidism - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Hypoparathyroidism - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hypoparathyroidism - Companies Involved in Therapeutics Development
- Aerami Therapeutics
- Alize Pharma III SAS
- Ascendis Pharma A/S
- BridgeBio Pharma Inc
- Chugai Pharmaceutical Co Ltd
- Eli Lilly and Co
- Entera Bio Ltd
- Extend Biosciences Inc
- GC Pharma
- ProLynx LLC
- Sigilon Therapeutics Inc
- Takeda Pharmaceutical Co Ltd
- Hypoparathyroidism - Drug Profiles
- ACP-014 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Aerami-701 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AZP-3601 - Drug Profile
- Product Description
- Mechanism Of Action

R&D Progress

encaleret - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXT-607 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-6272K - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

parathyroid hormone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PCO-371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Agonize PTH1R for Hypoparathyroidism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SIG-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SIG-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem cell Therapy for Hypoparathyroidism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teriparatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypoparathyroidism - Dormant Projects

Hypoparathyroidism - Product Development Milestones

Featured News & Press Releases

Apr 19, 2020: Ascendis Pharma announces top-line data from fixed dose portion of phase 2 trial demonstrating potential of TransCon PTH as a replacement therapy for Hypoparathyroidism

Nov 14, 2019: Ascendis Pharma expands TransCon PTH Phase 2 PaTH forward clinical trial to expedite enrollment of subjects previously treated with NATPARA in the United States

Oct 18, 2019: Leahy, Sanders, Welch urge FDA to swiftly resolve critical drug recall

Sep 23, 2019: Entera Bio reports positive results from a phase 2 PK/PD study of Oral PTH (1-34) in patients with Hypoparathyroidism

Sep 06, 2019: Takeda Issues US Recall of NATPARA (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate

May 15, 2019: Takeda to highlight new research into the long-term complications of chronic hypoparathyroidism at the European Congress of Endocrinology 2019 Annual Meeting

Apr 24, 2019: Ascendis Pharma announces presentations related to TransCon PTH at upcoming Medical Conferences

Mar 26, 2019: Takeda presents new data at the Endocrine Society's 2019 Annual Meeting about the patient burden and long-term impact of chronic hypoparathyroidism

Mar 26, 2019: Ascendis Pharma reports positive results from heiGHt trial

Mar 25, 2019: Ascendis Pharma announces results of study at ENDO 2019 evaluating impact of hypoparathyroidism on patient quality-of-life

Feb 12, 2019: Ascendis Pharma to study TransCon PTH for hypoparathyroidism

Nov 08, 2018: Entera Bio Reports Positive Results from Part 1 of a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism

Jun 06, 2018: Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism

May 22, 2018: Shire Announces New Hypoparathyroidism Data at the 2018 European Congress of Endocrinology

May 07, 2018: Ascendis Pharma Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hypoparathyroidism, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Hypoparathyroidism - Pipeline by Aerami Therapeutics, H1 2020

Hypoparathyroidism - Pipeline by Alize Pharma III SAS, H1 2020

Hypoparathyroidism - Pipeline by Ascendis Pharma A/S, H1 2020

Hypoparathyroidism - Pipeline by BridgeBio Pharma Inc, H1 2020

Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020

Hypoparathyroidism - Pipeline by Eli Lilly and Co, H1 2020

Hypoparathyroidism - Pipeline by Entera Bio Ltd, H1 2020

Hypoparathyroidism - Pipeline by Extend Biosciences Inc, H1 2020

Hypoparathyroidism - Pipeline by GC Pharma, H1 2020

Hypoparathyroidism - Pipeline by ProLynx LLC, H1 2020

Hypoparathyroidism - Pipeline by Sigilon Therapeutics Inc, H1 2020

Hypoparathyroidism - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Hypoparathyroidism - Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hypoparathyroidism, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Aerami Therapeutics

Alize Pharma III SAS

Ascendis Pharma A/S

BridgeBio Pharma Inc

Chugai Pharmaceutical Co Ltd

Eli Lilly and Co

Entera Bio Ltd

Extend Biosciences Inc

GC Pharma

ProLynx LLC

Sigilon Therapeutics Inc

Takeda Pharmaceutical Co Ltd

I would like to order

Product name: Hypoparathyroidism - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/HD54DD646F9EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HD54DD646F9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970